MDT · Healthcare

Medtronic plc

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-09-23

• Guidance / OutlookImportance 74 · Surprise 68
  Medtronic raised its fiscal 2027 full-year organic revenue growth guidance to 7.25%–7.75%. The increase followed Q1 FY27 results that produced approximately 7% organic revenue growth. The company also raised full-year…
• Guidance and OutlookImportance 74 · Surprise 68
  Medtronic raised its fiscal 2027 full-year organic revenue-growth guidance to 7.25%–7.75% after reporting approximately 7% organic growth in fiscal first-quarter 2027. Third-party coverage also reports that revenue and…
• Revenue Performance and MixImportance 43 · Surprise 32
  Medtronic delivered approximately 7% organic revenue growth in Q1 FY27. Cardiovascular and Neuroscience were identified as sources of notable strength in the quarter. Cardiac Ablation Solutions has become a meaningful…
• Minimally Invasive Robotic Surgery DemandImportance 42 · Surprise 64
  The global minimally invasive robotic surgical system market is projected to grow from $8.9 billion in 2025 to $18.15 billion by 2030, implying strong multi-year expansion. Demand is being supported by precision and…
• Portfolio Reshaping (M&A / Divestiture)Importance 40 · Surprise 42
  Medtronic’s MiniMed separation is expected to reduce the company’s size while improving profitability. The separation is intended to sharpen Medtronic’s focus on its core business segments. The digest does not disclose…
• MiniMed SeparationImportance 40 · Surprise 42
  Medtronic’s planned MiniMed separation is expected to reduce the company’s size while improving profitability. Coverage characterizes the transaction as a strategic refocusing on Medtronic’s core businesses. The…
• Gross Margin DriversImportance 23 · Surprise 24
  Medtronic is expected to realize margin expansion gradually as its product mix shifts toward higher-margin recurring revenues. The expected profitability improvement is also linked to the MiniMed separation. The digest…
• Cardiac Ablation ExpansionImportance 23 · Surprise 24
  Medtronic’s newer businesses, particularly Cardiac Ablation Solutions, are becoming meaningful contributors to its growth profile. The business is positioned as a driver of stronger demand within Medtronic’s…
• Dividend DeclarationImportance 13 · Surprise 6
  Medtronic declared a quarterly dividend of $0.72 per share. The dividend was associated with an approximately 3% indicated yield in the September 23, 2026 coverage. The digest does not state the payment date, record…
• Free Cash FlowImportance 10 · Surprise 6
  Medtronic was described as having strong free-cash-flow growth in coverage published on September 23, 2026. The company’s approximately 3% dividend yield was presented alongside that free-cash-flow profile. The digest…

News · 2026-09-22

• Revenue Performance and MixImportance 49 · Surprise 22
  Medtronic reported quarterly revenue of $9.76 billion, up 13.7% year over year. Quarterly EPS was $1.45, exceeding expectations alongside the revenue beat. The digest did not provide a segment-level revenue breakdown…
• Guidance / OutlookImportance 48 · Surprise 60
  Medtronic raised its non-GAAP EPS guidance for fiscal 2027 after reporting stronger-than-expected first-quarter results. The reported outlook change indicates improved management expectations for earnings during…
• Dividend DeclarationImportance 9 · Surprise 6
  Medtronic declared a quarterly dividend of $0.72 per share. The dividend was reported alongside quarterly revenue of $9.76 billion and EPS of $1.45. The digest did not state the record date, payment date, or any change…

News · 2026-09-17

• Guidance / OutlookImportance 73 · Surprise 76
  Medtronic raised its fiscal 2027 revenue and profit outlook for the second time on September 17, 2026. First-quarter revenue was $9.76 billion and adjusted earnings per share was $1.45, both above analyst expectations.…
• Hugo Robotic Surgery ExpansionImportance 38 · Surprise 60
  The FDA cleared Medtronic’s LigaSure RAS Maryland jaw device for use with the Hugo robotic-assisted surgery system in the United States. The clearance brings LigaSure vessel-sealing and cutting technology to U.S.…

News · 2026-09-16

• Management ChangesImportance 31 · Surprise 42
  Medtronic appointed Lara Barghout as president of its Interventional Cardiology Therapies operating unit on September 16, 2026. Barghout previously served as CEO of Recor Medical and led development of the Paradise…
• Regulatory Approval MilestonesImportance 7 · Surprise 60
  The U.S. FDA cleared Medtronic’s LigaSure RAS Maryland jaw device for use with the Hugo robotic-assisted surgery system on September 16, 2026. The instrument seals and cuts vessels up to 7mm and operates with the…
• Hugo Robotic Surgery ExpansionImportance 7 · Surprise 60
  The U.S. FDA cleared Medtronic’s LigaSure™ RAS Maryland jaw device for use with the Hugo™ robotic-assisted surgery system. The instrument brings Medtronic’s LigaSure vessel-sealing technology, used in more than 45…

News · 2026-09-15

• MiniMed SeparationImportance 46 · Surprise 42
  Medtronic launched an exchange offer to separate its MiniMed diabetes business into an independent company. The transaction is intended to let Medtronic concentrate capital on its cardiovascular, neuroscience, and…
• Diabetes Business SeparationImportance 46 · Surprise 42
  Medtronic launched an exchange offer to separate its diabetes business, MiniMed, into an independent company. Chief Executive Officer Geoff Martha cited MiniMed’s results, innovation pipeline, and market position as…
• Licensing / Collaboration DealsImportance 31 · Surprise 42
  Medtronic and Sonus Microsystems are integrating the Sonus Patch, an AI-powered wearable ultrasound platform, with Medtronic’s vital-sign monitoring technology. The partners plan field studies in Kenya focused on…
• AI Maternal Health PartnershipImportance 31 · Surprise 42
  Medtronic partnered with Sonus Microsystems to integrate the Sonus Patch AI-powered wearable ultrasound platform with Medtronic’s vital-sign monitoring technology. Field studies will be conducted in Kenya and funded by…
• Strategic InitiativesImportance 31 · Surprise 42
  Medtronic Chief Financial Officer Thierry Piéton identified acute procedures, the expanding innovation pipeline, and targeted acquisitions as strategic drivers of growth momentum. The reported priorities include…
• Products and TechnologyImportance 23 · Surprise 24
  Medtronic’s reported growth priorities include artificial intelligence, ablation, and acute procedures. The company is also emphasizing an expanding innovation pipeline to support its medical-device portfolio. The…
• Quarterly Earnings and DividendImportance 13 · Surprise 6
  Medtronic reported quarterly revenue of $9.76 billion and adjusted EPS of $1.45, exceeding earnings expectations. The company announced a quarterly dividend of $0.72 per share. The dividend implies a reported yield of…

News · 2026-09-14

• MiniMed SeparationImportance 65 · Surprise 60
  Medtronic commenced an exchange offer to separate at least 80.1% of MiniMed Group, Inc. from Medtronic. Shareholders may exchange Medtronic ordinary shares for MiniMed shares in a transaction intended to be generally…

News · 2026-09-12

• Quarterly Earnings and DividendImportance 35 · Surprise 22
  Medtronic reported earnings of $1.45 per share, exceeding analyst expectations. Revenue reached $9.76 billion, up 13.7% year over year. Medtronic recently declared a quarterly dividend of $0.72 per share. The reported…

News · 2026-09-11

• Guidance / OutlookImportance 47 · Surprise 60
  Medtronic raised its fiscal 2027 outlook following quarterly revenue of $9.76 billion and adjusted EPS of $1.45. The outlook increase was attributed to accelerating growth in cardiovascular devices. The report did not…
• Revenue Performance and MixImportance 44 · Surprise 40
  Medtronic reported quarterly revenue of $9.76 billion, up 13.7% year over year. Adjusted EPS was $1.45 for the quarter, exceeding analysts’ expectations. Accelerating cardiovascular-device growth was identified as a…
• Cardiac Device DemandImportance 23 · Surprise 24
  Third-party reporting describes strong and accelerating growth in Medtronic’s cardiovascular-device business. The reported demand momentum is identified as a key factor behind the company’s improved fiscal 2027…
• Dividend DeclarationImportance 13 · Surprise 6
  Medtronic declared a quarterly dividend of $0.72 per share. At the reported share price, the dividend represented an approximately 3.1% yield. The payment supports Medtronic’s progression toward Dividend King status,…

News · 2026-09-10

• Revenue Performance and MixImportance 47 · Surprise 22
  Medtronic reported quarterly revenue of $9.76 billion. Revenue increased 13.7% year over year. The company’s quarterly EPS was $1.45, and results exceeded analyst expectations.
• Guidance / OutlookImportance 47 · Surprise 60
  Medtronic reportedly raised its guidance following strong first-quarter fiscal 2027 results. The update indicates management expects continued organic revenue growth during fiscal 2027. The digest does not provide the…
• Diabetes Business SeparationImportance 34 · Surprise 42
  Medtronic is moving toward separating its diabetes division. The reported strategic rationale is that the business may face pressure from the increasing use of GLP-1 drugs. The separation is described as a near-term…
• Dividend DeclarationImportance 13 · Surprise 6
  Medtronic declared a quarterly dividend of $0.72 per share. The dividend was reported alongside quarterly revenue of $9.76 billion and EPS of $1.45. The declaration provides a recurring cash return to shareholders…

News · 2026-09-09

• Guidance / OutlookImportance 49 · Surprise 60
  Medtronic raised its fiscal 2027 organic revenue-growth outlook and increased the lower end of its adjusted earnings forecast. Management attributed the improved outlook to broad-based growth and stronger demand for…
• Revenue Performance and MixImportance 43 · Surprise 22
  Medtronic reported quarterly revenue of $9.76 billion, representing 13.7% year-over-year growth. Cardiovascular devices were a key growth driver, with particularly strong demand for pulsed field ablation products. The…
• Cardiac Device DemandImportance 23 · Surprise 24
  Medtronic reported strong demand for cardiovascular devices, with pulsed field ablation products identified as a key growth driver. The company is also investing in heart-valve technology and surgical robotics to…
• Dividend DeclarationImportance 13 · Surprise 6
  Medtronic declared a quarterly dividend of $0.72 per share. The dividend implied a reported yield of approximately 3.1% at the time of coverage. At the declared quarterly rate, the annualized cash distribution was…

News · 2026-09-05

• Dividend DeclarationImportance 20 · Surprise 6
  Medtronic declared a quarterly dividend of $0.72 per share. The dividend was reported alongside fiscal 2027 first-quarter revenue of $9.76 billion and adjusted EPS of $1.45. At the cited share price, the dividend…

News · 2026-09-04

• Guidance and OutlookImportance 51 · Surprise 60
  Medtronic raised its fiscal 2027 adjusted EPS guidance after reporting better-than-expected first-quarter results. Third-party coverage attributes the improved outlook to broader growth across major franchises and…

10-Q · 2026-09-03

• Goodwill Impairment RiskImportance 61 · Surprise 32
  Medtronic’s fiscal 2026 annual impairment analysis found that the Medical Surgical reporting unit’s estimated fair value exceeded its carrying value by approximately 12%, with $19.7 billion of goodwill allocated to the…
• SPR Therapeutics AcquisitionImportance 59 · Surprise 60
  Medtronic acquired all outstanding equity of privately held SPR Therapeutics, Inc. on July 16, 2026, for $654 million of total consideration transferred. The transaction strengthens the Neuromodulation division within…
• AI-Assisted Surgery PlatformImportance 57 · Surprise 76
  Cranial & Spinal Technologies sales increased 13%, driven by continued adoption of the AiBLE ecosystem, which integrates spine implants with StealthStation, O-arm imaging, Midas Rex, the Mazor robotic guidance…
• Revenue Performance and MixImportance 54 · Surprise 40
  Total net sales increased 14% year over year to $9.756 billion for the three months ended July 31, 2026, from $8.578 billion, including an estimated $570 million benefit from the 53rd fiscal week and favorable…
• Gross Margin DriversImportance 54 · Surprise 40
  Cost of products sold increased to $3.4 billion for the three months ended July 31, 2026, from $3.0 billion in the prior-year period. Cost of products sold as a percentage of net sales was flat year over year despite…
• Liquidity and Debt PositionImportance 54 · Surprise 14
  Cash and cash equivalents were $1.7 billion and current investments were $7.1 billion at July 31, 2026. Total debt was $28.2 billion, up from $28.0 billion at April 24, 2026, primarily because of higher short-term…
• Neuroscience Product AdoptionImportance 54 · Surprise 40
  Neuroscience sales grew 10%, with Cranial & Spinal Technologies up 13% on continued adoption of the AiBLE ecosystem, Core Spine, and Neurosurgery. Specialty Therapies increased 10%, driven by Altaviva, ENT,…
• Acute Care Product DemandImportance 48 · Surprise 40
  Acute Care & Monitoring sales increased 14%, primarily due to growth in Nellcor pulse oximetry, the McGRATH MAC video laryngoscope, and Microstream Capnography. Medtronic expects continued acceptance and growth in…
• Operating Expense TrendsImportance 47 · Surprise 22
  Research and development expense increased 6% to $771 million for the three months ended July 31, 2026, from $726 million in the prior-year period. Selling, general, and administrative expense increased approximately…
• Cardiac Device DemandImportance 46 · Surprise 56
  Electrophysiology Therapies sales increased 30%, driven by growth in the pulsed field ablation portfolio and higher demand for Cardiac Pacing Therapies and Defibrillation Solutions. The company expects continued…
• Diabetes Business SeparationImportance 44 · Surprise 60
  Medtronic announced in May 2025 that it intended to separate its Diabetes Business into a new independent publicly traded company, MiniMed Group, Inc. MiniMed completed an initial public offering on March 9, 2026, but…
• Sphere-9 Ventricular Ablation ExpansionImportance 44 · Surprise 60
  Medtronic expanded the commercial opportunity for the Affera Mapping and Ablation System and Sphere-9 catheter through an expanded CE Mark indication in August 2026 for treatment of ventricular arrhythmias. The…
• Capital Return ProgramImportance 40 · Surprise 42
  Medtronic’s March 2024 board authorization permits up to $5.0 billion of ordinary-share repurchases without a specified expiration date. During the three months ended July 31, 2026, Medtronic repurchased 3 million…
• Income Tax Rate ChangesImportance 38 · Surprise 58
  Medtronic’s effective tax rate declined to 16.4% for the three months ended July 31, 2026, from 19.6% in the prior-year period. The reduction primarily reflected the release of reserves for uncertain tax positions on…
• Trade Policy and TariffsImportance 37 · Surprise 42
  The U.S., China, and other jurisdictions have imposed or proposed additional tariffs on imported goods, creating uncertainty for Medtronic’s cost structure and financial performance. On February 20, 2026, the U.S.…
• Pillar Two Global Minimum TaxImportance 37 · Surprise 42
  The OECD Pillar Two Model Rules require large multinational corporations to pay a minimum 15% tax rate in each jurisdiction where they operate. Countries including Ireland have enacted legislation implementing the core…
• Hugo Robotic Surgery ExpansionImportance 31 · Surprise 32
  Surgical & Endoscopy sales increased 9%, supported by growth in LigaSure vessel sealing technology, V-Loc sutures, ProGrip mesh, the Hugo robotic-assisted surgery system, and Endoscopy. Medtronic expects global…
• Cardiovascular Product GrowthImportance 30 · Surprise 40
  Interventional Cardiology Therapies sales increased 7%, led by TAVR, the Symplicity Spyral renal denervation system, guide catheters, and balloons. CardioVascular Surgery sales increased 9%, supported by Aortic…
• Italian Payback Accrual ChangesImportance 28 · Surprise 42
  A June 30, 2025 Legislative Decree issued by the Italian government, formalized into law in August 2025, changed estimates for Italian payback accruals covering 2015 through 2018. The adjustment reduced net sales by…